- Zhifei Biological’s net income for the first quarter is 1.46 billion yuan.
- There has been a decrease in net income by 28% year on year.
- The reported revenue for the same quarter is 11.4 billion yuan.
- The revenue indicates a rise of 1.8% year on year.
- The noted revenue has surpassed the estimate of 11.23 billion yuan.
- A total of 26 buys, 1 hold, and 0 sells have been recorded for the company’s stocks.
- The comparisons to past results are based on values reported by the company’s original disclosures.
A look at Chongqing Zhifei Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Chongqing Zhifei Biological Products Company Ltd is looking towards a promising long-term future as indicated by its Smartkarma Smart Scores. With a solid Growth score of 5, the company demonstrates strong potential for expansion and development in the market. Additionally, the company has achieved respectable scores in Resilience and Momentum, showing that it is well-positioned to withstand challenges and maintain a stable upward trajectory.
While Chongqing Zhifei Biological Products may have room to improve in terms of Value and Dividend scores, its overall outlook appears positive with a focus on growth and resilience. The company’s dedication to researching, manufacturing, and selling vaccines and biological products positions it as a key player in the industry, making it one to watch for investors seeking opportunities in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
